Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LFA102 · 2 trials · 4 indications
Frequency and severity of dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| LFA102 | EXPERIMENTAL | - |
| Breast & Prostate Cancer Group | EXPERIMENTAL | Dose Escalation |
| Breast Cancer Group | EXPERIMENTAL | Dose Expansion |
| Prostate Cancer Group | EXPERIMENTAL | Dose Expansion |
| Uterine Leiomyoma Group | EXPERIMENTAL | Dose Expansion |
| Name | Type | Description |
|---|---|---|
| LFA102 | DRUG | - |
Inclusion Criteria: * Histologically confirmed diagnosis of prostate cancer * Histologically or cytologically confirmed locally advanced or metastatic breast cancer Exclusion Criteria: * Patients with untreated and/or symptomatic metastatic CNS disease * Prior anaphylactic or other severe infusio...
LFA102 is an investigational small molecule being studied for the treatment of castration-resistant prostate cancer and advanced or metastatic breast cancer. It has been evaluated in Phase 1 clinical trials in patients with prolactin receptor-positive tumors, including castration-resistant prostate cancer and metastatic breast cancer.
LFA102 is being developed by Novartis AG, a global pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company has sponsored Phase 1 clinical trials to evaluate the safety and efficacy of LFA102 in oncology indications.
LFA102 is in Phase 1 clinical development. It has completed Phase 1 trials, including a study in patients with prolactin receptor-positive castration-resistant prostate cancer or metastatic breast cancer, and a separate Phase 1 study in Japanese patients. LFA102 is investigational and not yet approved.
LFA102 has been studied in two completed Phase 1 clinical trials. The first, NCT01338831, enrolled 73 patients with prolactin receptor-positive castration-resistant prostate cancer or metastatic breast cancer. The second, NCT01610050, enrolled 14 Japanese patients with castration-resistant prostate cancer or advanced breast cancer.
LFA102 targets the prolactin receptor, as indicated by its clinical trials which enrolled patients with prolactin receptor-positive tumors. The drug is being studied in oncology indications including castration-resistant prostate cancer and advanced or metastatic breast cancer, where prolactin receptor expression is relevant.
LFA102 is not known to have alternative names. It is a distinct investigational small molecule developed by Novartis AG. In clinical trials, it is referred to solely as LFA102, and no other names or aliases have been associated with this drug candidate.